Human Organotypic Cultured Cardiac Slices: New Platform For High Throughput Preclinical Human Trials

Area of Science:

• Cardiovascular Research
• Translational Medicine
• Preclinical Drug Development

Background:

• Translation of novel therapies is hindered by human-animal genetic and physiological differences.
• A clinically relevant human model is needed to test therapy efficacy and cardiotoxicity.
• Existing models like human iPS-derived cardiomyocytes lack native tissue architecture.

Purpose of the Study:

• To develop and validate a preclinical platform using organotypic human heart slices.
• To enable testing of novel therapies in a physiologically relevant human heart model.
• To facilitate rapid therapy development by assessing efficacy and cardiotoxicity.

Main Methods:

• Organotypic slices were isolated from donor and end-stage failing human hearts.
• Optical mapping of transmembrane potential and calcium transients was used for validation.
• Physiology was assessed during culture to evaluate acute and chronic effects of therapies.

Main Results:

• Human heart slice preparations preserved normal electrophysiology, including sinus node function.
• Native tissue architecture and extracellular matrix were maintained, allowing investigation of multicellular physiology.
• Physiology remained stable during culture, supporting assessment of various therapeutic interventions.

Conclusions:

• Organotypic human heart slices provide a powerful, high-throughput preclinical platform.
• This model system allows investigation of multicellular physiology in normal and diseased myocardium.
• The platform facilitates rapid assessment of human heart responses to novel therapies and diseases.